American Association for Cancer Research
10780432ccr140861-sup-129520_1_supp_2617706_ndj4wq.docx (15.52 kB)

Supplementary Figure Legends from PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis

Download (15.52 kB)
journal contribution
posted on 2023-03-31, 18:50 authored by Lucia B. Jilaveanu, Fabio Parisi, Meaghan L. Barr, Christopher R. Zito, William Cruz-Munoz, Robert S. Kerbel, David L. Rimm, Marcus W. Bosenberg, Ruth Halaban, Yuval Kluger, Harriet M. Kluger

This file provides legends for Supplementary Figures S1, S2, S3 and S4. Figure S1 contains Kaplan Meier survival curves for PLEKHA5 expression and metastases to various sites, Figures S2 and S3 show Western blots demonstrating PLEKHA5 expression in cells transfected and untransfected with siRNA for PLEKHA5, and Figure S4 shows the effect of astrocytes on PLEKHA5 silencing and cell viability in A375Br cells.



Purpose: Approximately 40% of patients with metastatic melanoma develop brain metastases. Our purpose was to identify genes aberrantly expressed in melanoma that might be associated with propensity for brain homing.Experimental Design: We studied gene expression profiles in a cell line model of brain metastasis (cerebrotropic A375Br cells vs. parental A375P cells) and compared them with profiles of patients who developed early brain metastases and who did not. A tissue microarray containing 169 metastatic melanoma cases with variable time to brain metastasis was constructed to further study marker expression by quantitative immunofluorescence. An in vitro model of the blood brain barrier (BBB) was generated to evaluate potential mediators of brain metastases.Results: PLEKHA5 was differentially expressed in both the A375 cell line model and patient samples subjected to gene expression profiling. At the protein level, by quantitative immunofluorescence, PLEKHA5 was associated with decreased brain metastasis-free survival. PLEKHA5 overexpression was not associated with other metastatic sites. Knockdown of PLEKHA5 decreases the viability of A375Br cells, inhibits BBB transmigration and invasion in vitro. Similar results were found with YUMUL cells, cultured from a patient with overwhelming brain metastases. PLEKHA5 knockdown did not affect the viability of A375P cells.Conclusions: PLEKHA5 expression in melanoma tumors was associated with early development of brain metastases. Inhibition of PLEKHA5 might decrease passage across the BBB and decrease proliferation and survival of melanoma cells both in the brain and in extracerebral sites. Clin Cancer Res; 21(9); 2138–47. ©2014 AACR.See related commentary by Eisele et al., p. 1978